Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 60%
Buy 33%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc is experiencing a positive outlook driven by increased revenue estimates for its products, particularly the Brinsupri NCFB, which has seen its peak sales estimate rise to approximately $8.5 billion, reflecting enhanced market confidence. The company is also adjusting revenue projections for its emerging therapies, including Treprostinil Palmitil Inhalation Powder for idiopathic pulmonary fibrosis (IPF), suggesting a diversified and strengthening pipeline. Additionally, a reduced terminal decline rate in the discounted cash flow (DCF) analysis indicates heightened confidence in the longevity and sustainability of Insmed's revenue generation potential.

Bears say

Insmed Inc faces significant risks related to potential delays in clinical trials and regulatory approvals for its key products, which could adversely impact the company's overall valuation. Specifically, both Brensocatib and Treprostinil Palmitil Inhalation Powder are likely to encounter extensive timelines, with estimates suggesting TPIP may not penetrate the idiopathic pulmonary fibrosis (IPF) market until 2034, contingent on other drug approvals. Such delays in product development and market entry could significantly diminish the probability of success for Insmed, leading to a negative financial outlook.

Insmed (INSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 33% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 15 analysts, Insmed (INSM) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.